April 7, 2014

Boehringer Ingelheim Pharmaceuticals announced that the Food and Drug Administration has approved Pradaxa (dabigatran etexilate mesylate), which is used to treat deep venous thrombosis and pulmonary embolism.

August 15, 2013

Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital on a long-term study program to assess comparative effectiveness and safety, as well as prescribing patterns, of oral anticoagulants, including Pradaxa, for the reduction of stroke risk in U.S. patients with non-valvular atrial fibrillation.

November 14, 2011

A drug under development by Pfizer and Bristol-Myers Squibb for preventing internal blood clots failed to show superiority over a treatment already on the market, the companies said Monday.

August 29, 2011

A drug made by Pfizer and Bristol-Myers Squibb undergoing late-stage clinical trials was more effective than the generic drug warfarin in patients with atrial fibrillation, according to study results released Sunday.

May 19, 2011

A drug for cardiovascular disease made by Boehringer Ingelheim has received preferred formulary status with AARP’s Medicare Part D plans, the drug maker said Thursday.

March 15, 2011

A drug used to prevent stroke in patients with a form of atrial fibrillation has won preferred Tier 2 formulary status with pharmacy benefit managers Medco Health Solutions and CVS Caremark.

October 19, 2010

The Food and Drug Administration approved a drug for preventing strokes and blood clots in...

September 20, 2010

A Food and Drug Administration advisory committee has recommended approval of a drug for patients...

July 6, 2010

Launch and use of new heart drugs will drive the market for drugs to treat...